tert-butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)piperidine-1-carboxylate

Catalog No.: 
ACUZBA032
CAS No.: 
2241315-05-7
Molecular Formula: 
C27H37N5O5
Molecular Weight: 
511.62
tert-butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$350.00In stock1 week
250mg95%$700.00In stock1 week
1g95%$1992.00In stock1 week

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)piperidine-1-carboxylate
Molecular FormulaC27H37N5O5
Molecular Weight511.62
SMILESCC(C)(C)OC(=O)N1CCC(N2CCN(C3=CC=C4C(=O)N(C5CCC(=O)NC5=O)CC4=C3)CC2)CC1
InChI KeyYRTYFEWYCFFVDU-UHFFFAOYSA-N
CAS No.2241315-05-7

Synthetic Route by SureRoute

1. ACUZBA032 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWNGA479 route compound structure diagram
    ACWNGA479177276-41-4In Stock
  2. Plus
  3. ACDVTN981 route compound structure diagram
    ACDVTN9811010100-26-1In Stock
  4. Then
  5. ACUZBA032 route product structure diagram
    ACUZBA0322241315-05-7In Stock
Inquiry

2. ACUZBA032 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACOEWJ159 route compound structure diagram
    ACOEWJ1592222120-31-0In Stock
  4. Then
  5. ACUZBA032 route product structure diagram
    ACUZBA0322241315-05-7In Stock
Inquiry

3. ACUZBA032 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUZBA032 route product structure diagram
    ACUZBA0322241315-05-7In Stock
Inquiry

Comments (0)